




UK Standards for Microbiology Investigations

Identification of Anaerobic Gram Negative Rods



Acknowledgments

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see <https://www.gov.uk/government/groups/standards-for-microbiology-investigations-steering-committee>).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content.

For further information please contact us at:

Standards Unit
Microbiology Services
Public Health England
61 Colindale Avenue
London NW9 5EQ

E-mail: standards@phe.gov.uk

Website: <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>

PHE Publications gateway number: 2015013

UK Standards for Microbiology Investigations are produced in association with:



Logos correct at time of publishing.

Contents

ACKNOWLEDGMENTS	2
AMENDMENT TABLE	4
UK STANDARDS FOR MICROBIOLOGY INVESTIGATIONS: SCOPE AND PURPOSE.....	5
SCOPE OF DOCUMENT	8
INTRODUCTION	8
TECHNICAL INFORMATION/LIMITATIONS.....	10
1 SAFETY CONSIDERATIONS	12
2 TARGET ORGANISMS.....	12
3 IDENTIFICATION.....	13
4 PRESUMPTIVE IDENTIFICATION OF ANAEROBIC GRAM NEGATIVE RODS.....	17
5 REPORTING	18
6 REFERRALS.....	18
7 NOTIFICATION TO PHE OR EQUIVALENT IN THE DEVOLVED ADMINISTRATIONS	19
REFERENCES	20



NICE has accredited the process used by Public Health England to produce Standards for Microbiology Investigations. Accreditation is valid for 5 years from July 2011. More information on accreditation can be viewed at www.nice.org.uk/accreditation.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Amendment table

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from standards@phe.gov.uk.

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.

Amendment No/Date.	5/29.06.15
Issue no. discarded.	1.4
Insert Issue no.	2
Section(s) involved	Amendment
Whole document.	Hyperlinks updated to gov.uk.
Page 2.	Updated logos added.
Introduction.	The taxonomy of Anaerobic Gram Negative Rods has been updated. More information has been added to the Characteristics section. The medically important species are mentioned.
Technical information/limitations.	Addition of information regarding Gram stain, Agar media, metronidazole susceptibility, commercial identification systems and MALDI-TOF MS.
Target organisms.	The section on the Target organisms has been updated and presented clearly for all the organisms.
Identification.	Updates have been done on 3.2, 3.3 and 3.4 to reflect standards in practice. Section 3.4.2 and 3.4.3 has been updated to include MALDI-TOF MS and NAATs with references. Subsection 3.5 has been updated to include the Rapid Molecular Methods.
Identification flowchart.	Modification of flowchart for identification of Anaerobic Gram negative rods has been done for easy guidance.
Referral.	The addresses of the reference laboratories have been updated.
References.	Some references updated.

UK Standards for Microbiology Investigations[#]: scope and purpose

Users of SMIs

- SMIs are primarily intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK
- SMIs provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests
- SMIs provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population

Background to SMIs

SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages.

Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

Equal partnership working

SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies.

The list of participating societies may be found at <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>.

Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the Steering Committee and Working Groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process.

SMIs are developed, reviewed and updated through a wide consultation process.

[#]Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology.

Quality assurance

NICE has accredited the process used by the SMI Working Groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008.

SMIs represent a good standard of practice to which all clinical and public health microbiology laboratories in the UK are expected to work. SMIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIs also provide a reference point for method development.

The performance of SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

Patient and public involvement

The SMI Working Groups are committed to patient and public involvement in the development of SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

Information governance and equality

PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions.

The development of SMIs are subject to PHE Equality objectives <https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity>. The SMI Working Groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

Legal statement

Whilst every care has been taken in the preparation of SMIs, PHE and any supporting organisation, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made to an SMI, it must be made clear where and by whom such changes have been made.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the time of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIs are Crown copyright which should be acknowledged where appropriate.

Suggested citation for this document

Public Health England. (2015). Identification of Anaerobic Gram Negative Rods. UK Standards for Microbiology Investigations. ID 25 Issue 2. <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>

Scope of document

This SMI describes the characterisation of non-sporing, non-branching, Gram negative anaerobic bacteria.

Anaerobic spore-forming organisms are described in [ID 8 - Identification of *Clostridium* species](#), [ID 15 – Identification of anaerobic *Actinomyces* species](#) and [ID 10 - Identification of aerobic Actinomycetes](#).

Anaerobic cocci can be found in [ID 14 – Identification of anaerobic cocci](#).

This SMI should be used in conjunction with other SMIs.

Introduction

Taxonomy

The taxonomy of the anaerobic bacteria is in a state of continuous change due to the constant addition of new species and the reclassification of the old¹. An example of this would be the genus *Bacteroides*. This genus previously included most of the saccharolytic pigmented species that are now included in the genus *Prevotella* and the asaccharolytic species which have been assigned to the genus *Porphyromonas*^{2,3}.

There are more than 20 genera of anaerobic Gram negative rods. The most common human isolates belong to the genera *Bacteroides*, *Fusobacterium*, *Porphyromonas* and *Prevotella*. Other genera that have been associated with infections in humans are, *Parabacteroides*, *Odoribacter*, *Tannerella*, *Alloprevotella* and *Mitsuokella*¹.

Characteristics

***Bacteroides* species**

There are currently 44 validly published species. Twenty seven of which are from humans despite few taxonomic changes having occurred in the genus; new species described and some former species moved to other genera².

Bacteroides species belong to the family Bacteroidaceae and are short rod shaped organisms that vary in size; many of them are pleomorphic and show terminal or central swellings, vacuoles or filaments. *Bacteroides* are bile resistant, aesculin positive and carbohydrate fermenters. They are catalase variable but usually negative and do not reduce nitrates. They also give variable test results for indole production. They do not produce pigment.

Their optimal growth temperature is 35-37°C. On FAA plate, colonies appear as mostly non-haemolytic, circular, low convex, smooth, semi-opaque grey, often moist or even mucoid and are 1-3mm diameter.

Bacteroides fragilis is the most commonly isolated species from clinical samples. Other highly relevant species in human infections are *Bacteroides ovatus* and *Bacteroides thetaiotamicron*¹.

They have been isolated from blood, ulcers, abscesses, bronchial secretions, bone, intra-abdominal infections, inflamed appendix and the head⁴.

***Fusobacterium* species**

There are currently 14 validly published species and 10 of which have been isolated in humans⁵.

Fusobacterium species are rods which may be spindle-shaped eg *Fusobacterium nucleatum* or pleomorphic eg *Fusobacterium necrophorum*. They exhibit irregular staining. These two species are the most commonly isolated from human clinical material. *F. necrophorum* is a cause of serious infections (necrobacillosis or Lemièrre's disease) commonly diagnosed in young adults and also a cause of recurrent sore throats⁶.

Their optimal growth temperature is 35-37°C. Colonial appearance is variable, but most are 1-3 mm diameter, with an irregular or dentate edge. They vary from translucent to granular and opaque; *F. necrophorum* may be beta-haemolytic.

Fusobacterium species that are grown on fastidious anaerobe agar (FAA) containing blood may fluoresce yellow-green (chartreuse) when exposed to long wave (365 nm) ultraviolet light. This phenomenon is medium-dependent⁷. They are indole positive and fluoresce under UV light and produce lipase on egg yolk agar.

They have been isolated in root canal infections, dentoalveolar abscesses and spreading odontogenic infections. They have also been found in extraoral infections and abscesses in a wide range of body sites – blood, brain, chest, heart, lung, liver, appendix, abdomen, genitourinary tract, etc. as well as infected human bite lesions¹.

***Porphyromonas* species**

There are currently 15 validly published species and 7 of which have been isolated in humans⁸.

The genus *Porphyromonas* includes asaccharolytic, catalase negative species of human and animal origin. They are short rods (0.5 - 0.8 x 1.0 - 3.0µm) or coccobacilli and are bile sensitive.

Most *Porphyromonas* species isolated from humans are catalase negative whereas those from animals are catalase positive⁹.

Their optimal growth temperature is 35-37°C. On FAA plate, colonies are 1.0mm diameter, smooth, shiny and grey after 48hr incubation. Dark brown or black pigment develops after 3-7 days caused by protoheme production. Growth may be enhanced by "satellitism" around colonies of other organisms eg staphylococci.

Some *Porphyromonas* species may fluoresce brick red when exposed to long wave (365 nm) ultraviolet light and can produce a pigment (buff to tan to black) when grown on blood-containing media which is due to porphyrin production⁷.

***Prevotella* species**

There are currently 48 validly published species; 39 of which have been isolated in humans¹⁰. The genus *Prevotella* is composed of mainly saccharolytic, pigmented or non-pigmented species that were previously classified as *Bacteroides*, and these are usually pleomorphic.

Their optimal growth temperature is 35-37°C. On FAA plate, colonies are similar to those of *Bacteroides* species, except some species are pigmented (may be pale brown to black). Most pigmented species are haemolytic. Young cultures of *Prevotella* species may fluoresce brick red when exposed to long wave (365 nm) ultraviolet light,

and this may fade to a tan or black pigment when grown on blood-containing media for extended periods.

They give variable results on catalase test but are usually negative.

They have been isolated from nearly all oral infections, infected human bite lesions, genital tract infections, urine, blood, etc¹.

Principles of identification

Colonies are usually isolated on FAA (or equivalent) or blood agar and incubated anaerobically. Colonies can be characterised according to colonial morphology and Gram stain reaction and are usually sensitive to a 5µg metronidazole disc. Some species may require longer than 48 hours incubation to grow. Identification tends to be undertaken only if clinically indicated. Further identification tests include rapid molecular methods, fluorescence under long wave UV light (365 nm), pigment production, indole production, bile tolerance, glucose fermentation, and lecithinase and/or lipase activity on egg yolk agar. Classification of many anaerobes to species or even genus level requires additional biochemical tests or metabolic end product analysis by GLC.

Identification may be attempted using commercial kits but their results are not always reliable.

Identification of clinically significant or unusual organisms may be carried out by the Anaerobe Reference Laboratory, Cardiff. Clinical specimens for anaerobic culture should be cultured on a selective medium such as neomycin agar in addition to a non-selective fastidious anaerobe blood agar.

Technical information/limitations

Gram stain

There can be failure to determine the Gram reaction correctly (many anaerobes over decolourise and appear Gram negative). For example, *Clostridium* species that appear Gram negative on staining, especially *C. clostridioforme*, can be misidentified as *Bacteriodes*¹¹.

Agar media

Neomycin agar is used to inhibit the growth of facultative organisms in a mixed culture, but in certain instances because of the inhibitory aspects of the neomycin, some anaerobes may also not grow.

Susceptibility to metronidazole

In the clinical diagnostic laboratory, susceptibility to metronidazole is frequently used as an indicator of any anaerobe being present in a clinical specimen. However, an increasing number of metronidazole resistant anaerobes such as *Bacteroides fragilis* group are being recorded and these organisms may be missed by such an approach. It is important to consider anaerobes regardless of metronidazole susceptibility in certain clinical specimens or situations where anaerobes are suspected^{4,12}.

Commercial identification systems

Identification may be attempted using commercial kits but their results are not always reliable. These rapid easy to use systems have been used successfully for fast

growing and biochemically reactive anaerobes such as *B. fragilis* group organisms. However, some of these kits have incorrectly identified a number of clinically relevant species such as *F. necrophorum*, *P. intermedia* and *P. melaninogenica* as well as not being able to identify new species that are not in the system's limited database^{1,13}.

Another disadvantage of the automated commercial identification systems is its inability to differentiate between closely related species such as, *F. nucleatum* and *F. necrophorum*¹⁴.

MALDI-TOF MS

This technique has been successful as an aid in both the detection and species-level identification of *Bacteroides* species – *B. fragilis* group. However, database expansion could aid in the accurate species-level identification of *Bacteroides* species and perhaps enhance MALDI-TOF MS performance such that more discriminatory types of analysis could be performed, such as grouping of subspecies typing and antibiotic resistance determination among clinical isolates^{13,15}.

1 Safety considerations¹⁶⁻³²

Refer to current guidance on the safe handling of all organisms documented in this SMI.

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

The above guidance should be supplemented with local COSHH and risk assessments.

Compliance with postal and transport regulations is essential.

2 Target organisms^{1,4,6,33-36}

***Bacteroides fragilis* group reported to have caused human infection –**

B. cellulosilyticus, ***B. fragilis***, ***B. ovatus***, *B. caccae*, *B. stercoralis*, ***B. thetaiotaomicron***, *B. eggerthii*, *B. uniformis*, *B. vulgatus*, *B. clarus*, *B. coprocola*, *B. coprophilus*, *B. dorei*, *B. faecis*, *B. finegoldii*, *B. fluxus*, *B. galacturonicus*, *B. intestinalis*, *B. massiliensis*, *B. nordii*, *B. oleiciplenus*, *B. pectinophilus*, *B. plebius*, *B. salyersiae*, *B. xylanisolvans*, *B. pyogenes*

***Bacteroides* species (taxonomic position uncertain) reported to have caused human infection –**

B. coagulans

***Fusobacterium* species reported to have caused human infection –**

F. gonidiaformans, ***F. nucleatum*** - *F. nucleatum*, subspecies *fusiforme*, *F. nucleatum* subspecies *nucleatum*, *F. nucleatum* subspecies *polymorphum*, *F. nucleatum* subspecies *vincentii*, *F. mortiferum*, *F. necrogenes*, *F. naviforme*, *F. periodonticum*, ***F. necrophorum*** - *F. necrophorum* subspecies *funduliforme*, *F. necrophorum* subspecies *necrophorum*, *F. russii*, *F. ulcerans*, *F. varium*

***Porphyromonas* species reported to have caused human infection –**

P. asaccharolytica, *P. bennonis*, ***P. endodontalis***, *P. catoniae*, ***P. gingivalis***, *P. somerae*, *P. uenonis*

***Prevotella* species reported to have caused human infection –**

P. amnii, *P. aurantiaca*, *P. baroniae*, *P. bergensis*, *P. buccae*, *P. buccalis*, *P. bivia*, *P. dentalis*, *P. denticola**, *P. disiens*, *P. enoeca*, *P. heparinolytica*, *P. intermedia**, *P. copri*, *P. corporis**, *P. fusca*, *P. histicola*, *P. jejuni*, *P. loescheii**, *P. maculosa*, *P. marshii*, *P. micans*, *P. multiformis*, *P. multisaccharivorax*, *P. nanceiensis*, ***P. melaninogenica****, *P. nigrescens**, *P. oris*, *P. pallens*, *P. pleuritidis*, *P. oralis*, *P. oulorum*, *P. saccharolytica*, *P. salivae*, *P. scopos*, *P. shahii*, *P. stercorea*, *P. timonensis*, *P. veroralis*

Other reclassified species that have been associated with human disease –

Parabacteriodes distasonis, *Parabacteriodes goldsteinii*, *Parabacteriodes gordonii*, *Parabacteroides johnsonii*, *Parabacteriodes merdae*, *Tannerella forsythia*, *Mitsuokella multacida*, *Odoribacter splanchninus*, *Filifactor alocis*, *Eubacterium sulci*, *Alloprevotella tanneriae**, *Faecalibacterium prausnitzii*

* Pigmented species

3 Identification

3.1 Microscopic appearance

Gram stain ([TP 39 - Staining procedures](#))

Bacteroides, *Porphyromonas* and *Prevotella* species are small, Gram negative rods of variable length.

Fusobacterium species are Gram negative rods with unique cell morphology, highly variable in length and width, and they may have pointed ends. *F. nucleatum* usually exhibits long, spindle-shaped cells with tapered ends and is indole positive while *F. mortiferum* and *F. necrophorum* have highly pleomorphic cells, with or without swollen areas and large bodies and are indole and lipase positive.

3.2 Primary isolation media

Fastidious anaerobe agar or equivalent (with or without neomycin – some anaerobic organisms may be inhibited by neomycin) incubated for 40–48hr anaerobically at 35–37°C.

Note: some species of organisms such as *Porphyromonas* may require longer incubation¹.

3.3 Colonial appearance

Genus	Characteristics of growth on fastidious anaerobe agar after anaerobic incubation at 35-37°C
<i>Bacteroides</i>	Colonies are 1-3mm diameter, circular, low convex, smooth, semi-opaque grey and are often moist or even mucoid. Mostly non-haemolytic and resistant to an ox-bile disc.
<i>Fusobacterium</i>	Colonial appearance is variable, but most are 1-3mm diameter, with an irregular or dentate edge. They vary from translucent to granular and opaque; <i>F. necrophorum</i> may be beta-haemolytic. Indole positive, fluorescent yellow-green under long wave UV light.
<i>Porphyromonas</i>	Colonies are <1.0mm diameter after 48hr incubation, smooth, shiny and grey. Dark brown or black pigment develops after 3-7 days. Growth may be enhanced by "satellitism" around colonies of other organisms eg staphylococci.
<i>Prevotella</i>	Colonies are similar to those of <i>Bacteroides</i> species, except some species are pigmented (may be pale brown to black). Most pigmented species are haemolytic.

3.4 Test procedures

3.4.1 Biochemical tests

Susceptibility to metronidazole

Isolate shows a zone of inhibition to metronidazole 5µg discs after anaerobic incubation on a suitable agar medium.

Note: In the clinical diagnostic laboratory, susceptibility to metronidazole is frequently regarded as sufficient indicator of an anaerobe being present in a given specimen. Some anaerobes eg *B. fragilis* group are becoming resistant to metronidazole, and these organisms will be missed by such an approach^{4,12}. Colonies of suspected *Bacteroides* species resistant to metronidazole should be referred to the Anaerobe Reference Laboratory for confirmation.

AnIdent ring/discs

Follow manufacturer's instructions.

Aesculin hydrolysis test ([TP 2 - Aesculin hydrolysis test](#))

This may be used as a presumptive identification test for *Bacteroides fragilis* group as well as for differentiation of *Fusobacterium* species.

Bacteroides species are aesculin positive and *Fusobacterium* species are aesculin negative apart from *F. mortiferum* and *F. necrogenes*.

Catalase test ([TP 8 - Catalase test](#))

Bacteroides and *Prevotella* species give variable catalase reactions but are usually negative while *Fusobacterium* and *Porphyromonas* species are catalase negative.

Fluorescence under long wavelength UV light (365 nm)

Porphyromonas and *Prevotella* species may fluoresce orange to brick red, *Fusobacterium* species may fluoresce yellow-green (chartreuse) and *Bacteroides* species generally do not fluoresce.

Lipase/lecithinase production

Production of lipase or lecithinase may be used to differentiate *F. necrophorum* (lipase positive) from *F. nucleatum* (lipase negative).

Commercial identification systems

Laboratories should follow manufacturer's instructions and rapid tests and kits should be validated and be shown to be fit for purpose prior to use.

Results should be interpreted with caution in conjunction with other test results.

Note: Glucose fermentation may be used to differentiate *Prevotella* species from *Porphyromonas* species.

3.4.2 Matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) mass spectrometry

Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS), which can be used to analyse the protein composition of a bacterial cell, has emerged as a new technology for species identification. This has been shown to be a rapid and powerful tool because of its reproducibility, speed and sensitivity of analysis. The advantage of MALDI-TOF as compared with other identification methods is that the results of the analysis are available within a few hours rather than several days. The speed and the simplicity of sample preparation and result acquisition associated with minimal consumable costs make this method well suited for routine and high-throughput use³⁷.

This technique has been successful as an aid in both the detection and species-level identification of *Bacteroides* species – *B. fragilis* group. However, database expansion could aid in the accurate species-level identification of *Bacteroides* species and

perhaps enhance MALDI-TOF MS performance such that more discriminatory types of analysis could be performed, such as grouping of subspecies typing and antibiotic resistance determination among clinical isolates^{13,15}.

3.4.3 Nucleic acid amplification tests (NAATs)

PCR is usually considered to be a good method for bacterial detection as it is simple, rapid, sensitive and specific. The basis for PCR diagnostic applications in microbiology is the detection of infectious agents and the discrimination of non-pathogenic from pathogenic strains by virtue of specific genes. However, it does have limitations. Although the 16S rRNA gene is generally targeted for the design of species-specific PCR primers for identification, designing primers is difficult when the sequences of the homologous genes have high similarity.

This rapid method has been used successfully for the identification of *Bacteriodes fragilis* group species³⁸.

3.5 Further identification

Rapid molecular methods

Molecular methods have had an enormous impact on the taxonomy of Gram negative anaerobic bacteria. Analysis of gene sequences has increased understanding of the phylogenetic relationships of anaerobes and related organisms; and has resulted in the recognition of numerous new species. Molecular techniques have made identification of many species more rapid and precise than is possible with phenotypic techniques.

A variety of rapid typing methods have been developed for isolates from clinical samples; these include molecular techniques such as Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Analysis (PCR-RFLP), Multilocus Sequence Typing (MLST), *rpoB* rDNA sequencing and Whole Genome Sequencing (WGS). All of these approaches enable subtyping of unrelated strains, but do so with different accuracy, discriminatory power, and reproducibility.

However, some of these methods remain accessible to reference laboratories only and are difficult to implement for routine bacterial identification in a clinical laboratory.

rpoB rDNA sequencing

This method is being increasingly used for the identification of anaerobic bacteria, because sequencing of the gene is faster and more accurate than biochemical testing and, notably, independent of growth characteristics. *rpoB* genes are used as they have a greater resolving power than those for 16S genes, and because *rpoB* exists in the genome as a single gene, it is considered to have a faster evolutionary rate than 16S, and also, being a protein-coding gene, possesses fewer indel regions.

This has been successfully used for distinguishing *F. nucleatum* and *F. periodonticum*, and for oral isolates versus those isolated from intestinal biopsies^{1,39}.

However, sequencing, as a routine method may not be feasible for many clinical laboratories.

Polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP)

PCR amplification, followed by restriction digest analysis, is a simple technique that has been applied to species identification and could be used to analyse resistance

genes. Restriction fragment length polymorphism analysis of amplified small subunit rRNA gene (16S rDNA PCR-RFLP) has been shown to be a rapid, accurate, and effective method for the identification of clinically important anaerobes – for example, clostridia and actinomycetes.

This has been used successfully for improved identification of *Bacteroides* species and the detection of metronidazole (MTZ) resistance determinants⁴⁰. It has also been used for the differentiation of *P. intermedia* and *P. nigrescens*⁴¹.

Its advantages are its reliability, rapidity and accuracy. Another added advantage is that the method is inexpensive.

Multilocus sequence typing (MLST)

MLST measures the DNA sequence variations in a set of housekeeping genes directly and characterizes strains by their unique allelic profiles. The principle of MLST is simple: the technique involves PCR amplification followed by DNA sequencing. Nucleotide differences between strains can be checked at a variable number of genes depending on the degree of discrimination desired. The technique is highly discriminatory, as it detects all the nucleotide polymorphisms within a gene rather than just those non-synonymous changes that alter the electrophoretic mobility of the protein product. One of the advantages of MLST over other molecular typing methods is that sequence data are portable between laboratories and have led to the creation of global databases that allow for exchange of molecular typing data via the Internet⁴².

The drawbacks of MLST are the substantial cost and laboratory work required to amplify, determine, and proofread the nucleotide sequence of the target DNA fragments, making the method hardly suitable for routine laboratory testing.

This has demonstrated to be a valuable technique for the identification and classification of species of the genus *Bacteriodes*⁴³.


Other more specialized tests

Gas-Liquid Chromatography of metabolic end products.

3.6 Storage and referral

If required, for short term storage save the pure isolate in fastidious anaerobe broth with cooked meat for referral to the Reference Laboratory. Isolates may also be referred on swabs in transport media. For long term storage, cultures should be frozen at -70°C in a suitable cryogenic medium.

4 Presumptive identification of anaerobic gram negative rods



The flowchart is for guidance only.

5 Reporting

5.1 Presumptive identification

If appropriate growth characteristics, colonial appearance, Gram stain of the culture are demonstrated and the isolate is metronidazole susceptible.

5.2 Confirmation of identification

Further biochemical tests and/or molecular methods and/or reference laboratory report.

5.3 Medical microbiologist

Inform the medical microbiologist of presumptive or confirmed non-sporing anaerobes when the request bears relevant information eg:

- septicaemia/bacteraemia
- empyemas, surgical wound infection, abscess formation (especially cerebral, intraperitoneal, lung, liver or splenic abscesses)
- puerperal sepsis
- myofasciitis (necrotising)
- suspicion of Lemièrre's Syndrome (post anginal sepsis, often with jugular suppurative thrombophlebitis and haematogenous pulmonary abscesses)

Follow local protocols for reporting to clinician.

5.4 CCDC

Refer to local Memorandum of Understanding.

5.5 Public Health England⁴⁴

Refer to current guidelines on CIDSC and COSURV reporting.

5.6 Infection prevention and control team

N/A

6 Referrals

6.1 Reference laboratory

Contact appropriate devolved national reference laboratory for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission:

Anaerobe Reference Laboratory
Public Health Wales Microbiology Cardiff
University Hospital of Wales
Heath Park
Cardiff
CF14 4XW

<https://www.gov.uk/government/collections/anaerobe-reference-unit-arucardiff>

Telephone +44 (0) 29 2074 2171 or 2378

England and Wales

<https://www.gov.uk/specialist-and-reference-microbiology-laboratory-tests-and-services>

Scotland

<http://www.hps.scot.nhs.uk/reflab/index.aspx>

Northern Ireland

<http://www.belfasttrust.hscni.net/Laboratory-MortuaryServices.htm>

7 Notification to PHE^{44,45} or equivalent in the devolved administrations⁴⁶⁻⁴⁹

The Health Protection (Notification) regulations 2010 require diagnostic laboratories to notify Public Health England (PHE) when they identify the causative agents that are listed in Schedule 2 of the Regulations. Notifications must be provided in writing, on paper or electronically, within seven days. Urgent cases should be notified orally and as soon as possible, recommended within 24 hours. These should be followed up by written notification within seven days.

For the purposes of the Notification Regulations, the recipient of laboratory notifications is the local PHE Health Protection Team. If a case has already been notified by a registered medical practitioner, the diagnostic laboratory is still required to notify the case if they identify any evidence of an infection caused by a notifiable causative agent.

Notification under the Health Protection (Notification) Regulations 2010 does not replace voluntary reporting to PHE. The vast majority of NHS laboratories voluntarily report a wide range of laboratory diagnoses of causative agents to PHE and many PHE Health protection Teams have agreements with local laboratories for urgent reporting of some infections. This should continue.

Note: The Health Protection Legislation Guidance (2010) includes reporting of Human Immunodeficiency Virus (HIV) & Sexually Transmitted Infections (STIs), Healthcare Associated Infections (HCAs) and Creutzfeldt–Jakob disease (CJD) under ‘Notification Duties of Registered Medical Practitioners’: it is not noted under ‘Notification Duties of Diagnostic Laboratories’.

<https://www.gov.uk/government/organisations/public-health-england/about/our-governance#health-protection-regulations-2010>

Other arrangements exist in [Scotland](#)^{46,47}, [Wales](#)⁴⁸ and [Northern Ireland](#)⁴⁹.

contamination of the specimen. The manufacturing processes must be appropriate for these purposes".

17. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices. 7-12-1998. p. 1-37.
18. Health and Safety Executive. Safe use of pneumatic air tube transport systems for pathology specimens. 9/99.
19. Department for transport. Transport of Infectious Substances, 2011 Revision 5. 2011.
20. World Health Organization. Guidance on regulations for the Transport of Infectious Substances 2013-2014. 2012.
21. Home Office. Anti-terrorism, Crime and Security Act. 2001 (as amended).
22. Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive. 2013. p. 1-32
23. Advisory Committee on Dangerous Pathogens. Infections at work: Controlling the risks. Her Majesty's Stationery Office. 2003.
24. Advisory Committee on Dangerous Pathogens. Biological agents: Managing the risks in laboratories and healthcare premises. Health and Safety Executive. 2005.
25. Advisory Committee on Dangerous Pathogens. Biological Agents: Managing the Risks in Laboratories and Healthcare Premises. Appendix 1.2 Transport of Infectious Substances - Revision. Health and Safety Executive. 2008.
26. Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. MMWR Surveill Summ 2012;61:1-102.
27. Health and Safety Executive. Control of Substances Hazardous to Health Regulations. The Control of Substances Hazardous to Health Regulations 2002. 5th ed. HSE Books; 2002.
28. Health and Safety Executive. Five Steps to Risk Assessment: A Step by Step Guide to a Safer and Healthier Workplace. HSE Books. 2002.
29. Health and Safety Executive. A Guide to Risk Assessment Requirements: Common Provisions in Health and Safety Law. HSE Books. 2002.
30. Health Services Advisory Committee. Safe Working and the Prevention of Infection in Clinical Laboratories and Similar Facilities. HSE Books. 2003.
31. British Standards Institution (BSI). BS EN12469 - Biotechnology - performance criteria for microbiological safety cabinets. 2000.
32. British Standards Institution (BSI). BS 5726:2005 - Microbiological safety cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 24-3-2005. p. 1-14
33. Fenner L, Roux V, Mallet MN, Raoult D. *Bacteroides massiliensis* sp. nov., isolated from blood culture of a newborn. Int J Syst Evol Microbiol 2005;55:1335-7.
34. Legaria MC, Lumelsky G, Rodriguez V, Rosetti S. Clindamycin-resistant *Fusobacterium varium* bacteremia and decubitus ulcer infection. J Clin Microbiol 2005;43:4293-5.
35. Euzéby,JP. List of prokaryotic names with standing in nomenclature Genus *Tannerella*. 2013.

36. Euzéby,JP. List of prokaryotic names with standing in nomenclature Genus *Parabacteriodes*. 2013.
37. Barbuddhe SB, Maier T, Schwarz G, Kostrzewa M, Hof H, Domann E, et al. Rapid identification and typing of listeria species by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Appl Environ Microbiol* 2008;74:5402-7.
38. Liu C, Song Y, McTeague M, Vu AW, Wexler H, Finegold SM. Rapid identification of the species of the *Bacteroides fragilis* group by multiplex PCR assays using group- and species-specific primers. *FEMS Microbiol Lett* 2003;222:9-16.
39. Strauss J, White A, Ambrose C, McDonald J, Allen-Vercoe E. Phenotypic and genotypic analyses of clinical *Fusobacterium nucleatum* and *Fusobacterium periodonticum* isolates from the human gut. *Anaerobe* 2008;14:301-9.
40. Stubbs SL, Brazier JS, Talbot PR, Duerden BI. PCR-restriction fragment length polymorphism analysis for identification of *Bacteroides* spp. and characterization of nitroimidazole resistance genes. *J Clin Microbiol* 2000;38:3209-13.
41. Milsom SE, Sprague SV, Dymock D, Weightman AJ, Wade WG. Rapid differentiation of *Prevotella intermedia* and *P. nigrescens* by 16S rDNA PCR-RFLP. *J Med Microbiol* 1996;44:41-3.
42. Feil EJ, Spratt BG. Recombination and the population structures of bacterial pathogens. *Annu Rev Microbiol* 2001;55:561-90.
43. Sakamoto M, Ohkuma M. Identification and classification of the genus *Bacteroides* by multilocus sequence analysis. *Microbiology* 2011;157:3388-97.
44. Public Health England. Laboratory Reporting to Public Health England: A Guide for Diagnostic Laboratories. 2013. p. 1-37.
45. Department of Health. Health Protection Legislation (England) Guidance. 2010. p. 1-112.
46. Scottish Government. Public Health (Scotland) Act. 2008 (as amended).
47. Scottish Government. Public Health etc. (Scotland) Act 2008. Implementation of Part 2: Notifiable Diseases, Organisms and Health Risk States. 2009.
48. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010.
49. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967 (as amended).